We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter
Est. Return
+21.1%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow
% of AUM
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
MoonLake Immunotherapeutics
MLTX
$813M
| $20.4M | 0.71% |
+400,000
| New | +$10.8M |
2023 Q2
0 quarters
|
|
|
VRNA
52
DELISTED
Verona Pharma
VRNA
| $20.2M | 0.7% |
954,500
+75,700
| +9% | +$1.61M |
2023 Q1
1 quarter
|
|
53
Amylyx Pharmaceuticals
AMLX
$3.31B
| $19.4M | 0.68% |
901,400
+1,400
| +0.2% | +$37.8K |
2023 Q1
1 quarter
|
|
54
DELISTED
Axonics, Inc. Common Stock
AXNX
| $19.2M | 0.67% |
+379,700
| New | +$20.2M |
2023 Q2
0 quarters
|
|
55
Xenon Pharmaceuticals
XENE
$3.24B
| $18.5M | 0.65% |
+481,300
| New | +$19.1M |
2023 Q2
0 quarters
|
|
|
56
Regeneron Pharmaceuticals
REGN
$81.4B
| $17.8M | 0.62% |
24,800
-94,300
| -79% | -$72.7M |
2023 Q1
1 quarter
|
|
57
Roivant Sciences
ROIV
$24.2B
| $17M | 0.59% |
+1,687,500
| New | +$15.1M |
2023 Q2
0 quarters
|
|
58
Pliant Therapeutics
PLRX
$55.7M
| $16.6M | 0.58% |
916,600
-1,748,400
| -66% | -$41.4M |
2022 Q3
3 quarters
|
|
59
DELISTED
Verve Therapeutics
VERV
| $16.5M | 0.58% |
878,600
-473,100
| -35% | -$7.88M |
2022 Q3
3 quarters
|
|
60
Intellia Therapeutics
NTLA
$1.6B
| $16.1M | 0.56% |
395,855
-21,145
| -5% | -$857K |
2022 Q1
5 quarters
|
|
61
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $15.9M | 0.56% |
+501,200
| New | +$15.4M |
2023 Q2
0 quarters
|
|
62
DELISTED
ACELYRIN
SLRN
| $15.7M | 0.55% |
+750,000
| New | +$15.3M |
2023 Q2
0 quarters
|
|
|
PNT
63
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $15.1M | 0.53% |
1,671,800
-739,800
| -31% | -$6.52M |
2022 Q3
3 quarters
|
|
64
Karyopharm Therapeutics
KPTI
$8.85M
| $15M | 0.52% |
558,007
-84,254
| -13% | -$3.63M |
2022 Q4
2 quarters
|
|
65
DELISTED
Kezar Life Sciences
KZR
| $14.9M | 0.52% |
608,000
-43,940
| -7% | -$1.14M |
2021 Q3
7 quarters
|
|
66
Schrodinger
SDGR
$1.69B
| $13.7M | 0.48% |
+274,900
| New | +$9.29M |
2023 Q2
0 quarters
|
|
67
DELISTED
2seventy bio
TSVT
| $13.6M | 0.47% |
+1,342,000
| New | +$14.2M |
2023 Q2
0 quarters
|
|
68
Mineralys Therapeutics
MLYS
$1.79B
| $13.1M | 0.46% |
766,700
-497,100
| -39% | -$7.43M |
2023 Q1
1 quarter
|
|
69
DELISTED
Mersana Therapeutics
MRSN
| $12.5M | 0.44% |
151,600
+14,271
| +10% | +$2.09M |
2023 Q1
1 quarter
|
|
70
Caribou Biosciences
CRBU
$50.4M
| $11.7M | 0.41% |
2,758,600
| – | – |
2021 Q3
7 quarters
|
|
|
NSTG
71
DELISTED
NanoString Technologies, Inc.
NSTG
| $10.9M | 0.38% |
2,700,400
+483,400
| +22% | +$3.57M |
2022 Q3
3 quarters
|
|
72
DELISTED
Alpine Immune Sciences Inc
ALPN
| $10.9M | 0.38% |
1,058,500
+69,000
| +7% | +$622K |
2020 Q3
11 quarters
|
|
73
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $10.2M | 0.36% |
+175,000
| New | +$11M |
2023 Q2
0 quarters
|
|
74
DELISTED
89bio
ETNB
| $9.97M | 0.35% |
526,376
-1,316,600
| -71% | -$23.1M |
2023 Q1
1 quarter
|
|
75
AC Immune
ACIU
$238M
| $8.58M | 0.3% |
2,903,278
+2,577,878
| +792% | +$5.63M |
2022 Q3
3 quarters
|
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.